{
    "organizations": [],
    "uuid": "f34bd82ba674c7c68eb0a1e6e94485459242df7f",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/22/globe-newswire-chimerix-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-march-1-2018.html",
    "ord_in_thread": 0,
    "title": "Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "DURHAM, N.C., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2017, and to provide a business overview.\nTo access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1153769. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com . An archived webcast will be available on the Chimerix website approximately two hours after the event.\nAbout Chimerix\nChimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and Compound Library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus to enter clinical testing. For further information, please visit Chimerix's website, www.chimerix.com .\nCONTACT:\nInvestor Relations:\nMichelle LaSpaluto\n919-972-7115\nir@chimerix.com\nor\nWill O’Connor\nStern Investor Relations\nWill@sternir.com\n212-362-1200\nMedia:\nBecky Vonsiatsky\nW2O Group\nbvonsiatsky@w2ogroup.com\n413-478-2003\nSource:Chimerix, Inc.",
    "published": "2018-02-22T16:00:00.000+02:00",
    "crawled": "2018-02-22T17:53:51.183+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "durham",
        "globe",
        "newswire",
        "chimerix",
        "nasdaq",
        "cmrx",
        "biopharmaceutical",
        "company",
        "developing",
        "novel",
        "antiviral",
        "growing",
        "population",
        "immunocompromised",
        "patient",
        "today",
        "announced",
        "host",
        "live",
        "conference",
        "call",
        "audio",
        "webcast",
        "thursday",
        "march",
        "et",
        "report",
        "financial",
        "result",
        "fourth",
        "quarter",
        "full",
        "year",
        "ended",
        "december",
        "provide",
        "business",
        "overview",
        "access",
        "live",
        "conference",
        "call",
        "please",
        "dial",
        "domestic",
        "international",
        "least",
        "five",
        "minute",
        "prior",
        "start",
        "time",
        "refer",
        "conference",
        "id",
        "live",
        "audio",
        "webcast",
        "call",
        "also",
        "available",
        "investor",
        "section",
        "company",
        "website",
        "archived",
        "webcast",
        "available",
        "chimerix",
        "website",
        "approximately",
        "two",
        "hour",
        "event",
        "chimerix",
        "chimerix",
        "biopharmaceutical",
        "company",
        "dedicated",
        "discovering",
        "developing",
        "commercializing",
        "medicine",
        "improve",
        "outcome",
        "immunocompromised",
        "patient",
        "chimerix",
        "proprietary",
        "lipid",
        "conjugate",
        "technology",
        "compound",
        "library",
        "produced",
        "brincidofovir",
        "bcv",
        "cmx001",
        "cmx157",
        "licensed",
        "contravir",
        "pharmaceutical",
        "new",
        "clinical",
        "candidate",
        "cmx521",
        "first",
        "antiviral",
        "specifically",
        "treatment",
        "prevention",
        "norovirus",
        "enter",
        "clinical",
        "testing",
        "information",
        "please",
        "visit",
        "chimerix",
        "website",
        "contact",
        "investor",
        "relation",
        "michelle",
        "laspaluto",
        "ir",
        "connor",
        "stern",
        "investor",
        "relation",
        "medium",
        "becky",
        "vonsiatsky",
        "w2o",
        "group",
        "bvonsiatsky",
        "source",
        "chimerix",
        "inc"
    ]
}